Market News & Trends
Catalent & MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Catalent and MigVax recently announced they have signed a development agreement to leverage Catalent’s proprietary Zydis Bio orally disintegrating tablet (ODT) technology for delivering the…
Editas Medicine & Immatics Enter Strategic Research Collaboration & Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies & Gene Editing for the Treatment of Cancer
Editas Medicine, Inc. and Immatics N.V. recently announced the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and….
Apellis & Sobi Announce First Patient Dosed in Phase 3 Study of Pegcetacoplan for IC-MPGN & C3G, Rare Kidney Diseases With High Unmet Medical Need
Apellis Pharmaceuticals, Inc. and Sobi recently announced the first patient has been dosed in the Phase 3 VALIANT study investigating pegcetacoplan, a targeted C3 therapy,…
ProteoGenix, Aseem Healthcare & Trident Biopharm Solutions Announce New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2
ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions recently announced the development of a new antibody cocktail effective against major variants of SARS-CoV-2. The cocktail of…
Evonik Launches New Peptide to Boost Productivity of Cell-Culture-Based Biopharmaceuticals
Evonik now offers a highly pure cystine peptide to address challenges in the formulation of cell culture media and processes used in the development and…
SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022?
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities
Berkeley Lights, Inc. and Curia recently announced Curia’s adoption of The Beacon Optofluidic system and workflows from Berkeley Lights to accelerate….
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
Yumanity Therapeutics, Inc. recently announced it has entered into definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase….
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next-Generation Core Inhibitor
Assembly Biosciences, Inc. recently announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733 (3733). 3733 has demonstrated…
Jubilant HollisterStier Enters Cooperative Agreement With US Government to Expand Critical Vaccine Manufacturing Capacity
Jubilant Pharmova Limited recently announced that Jubilant Pharma Limited, a wholly owned subsidiary of the company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based….
Immunocore Announces Clinical Trial Collaboration With Sanofi
Immunocore Holdings Plc recently announced it has entered into a clinical trial collaboration and supply agreement with Sanofi…..
Zai Lab & Novocure Announce Phase 2 Pilot Study Evaluating Tumor Treating Fields Together With Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Zai Lab and Novocure recently announced the EF-31 Phase 2 pilot study, testing the safety and efficacy of Tumor Treating Fields (TTFields) together with standard-of-care…
Evonik Invests $220 Million to Build New Lipid Production Facility for mRNA-based Therapies in the US
Evonik is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the US. The new plant at Evonik’s Tippecanoe site in Lafayette,…
4P-Pharma & Delta 4 Join Forces to Find & Develop Treatments for a Rare Autoimmune Chronic Liver Disease
4P-Pharma and Delta 4 recently announced the signing of a collaboration agreement in which both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver….
Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor
Teon Therapeutics recently announced the acceptance by the US FDA of Teon’s Investigational New Drug (IND) application for the study of TT-816. TT-816 is a novel, oral cannabinoid CB2 receptor….
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate
PDS Biotechnology Corporation recently announced the US FDA has granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). PDS0101 in combination…
Biogen & Samsung Bioepis’ & Biogen's BYOOVIZ (ranibizumab-nuna) Launches in the US
Samsung Bioepis Co., Ltd. and Biogen Inc. recently announced BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab), has been launched….
Vaxart Reports Positive Preliminary Data from Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
Results of the trial show a robust immune response across all doses, with a dose-dependent production of IgA antibody secreting cells (ASCs), consistent with previous…
CordenPharma Increases xRNA-based Capabilities with a Strategic Investment in LNP Formulation Services at its Caponago Injectable Facility
CordenPharma has recently increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy. The company reports that it is investing over €10M in new Lipid Nanoparticle (LNP) formulation,….
Lonza Completes Dedicated Early Clinical Phase Development & Manufacturing Facility in Bend (OR)
Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at…
